Arcutis Biotherapeutics CEO Todd Watanabe sells $139,466 in stock

Arcutis Biotherapeutics CEO Todd Watanabe sold 4,377 shares of the company's common stock on November 2, 2026, amounting to $139,466. The shares were sold at an average price of $31.86, ranging from $31.57 to $32.23. The transaction was to cover tax withholding obligations for the vesting of Restricted Stock Units. Since the sale, Arcutis Biotherapeutics stock has increased to $34.05, near its 52-week high of $34.80, indicating a 45% gain over the past six months.

Analysts suggest the stock is slightly overvalued at current levels. Watanabe retains a substantial stake in the company, holding 712,826 shares directly and 25,410 shares indirectly through four trusts and two private companies. Despite a revenue beat of $143.9 million in Q3 2026, the company's adjusted earnings for the period were $0.06 per share, far below the expected $0.18 per share, impacting investor sentiment.

The earnings miss led to a significant post-market decline in the stock price. The company's focus now revolves around balancing revenue growth with profitability.